Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers
tiistai 11. kesäkuuta 2019 päivittänyt: GlaxoSmithKline
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine (GSK 134612) When Co-administered With Routine Vaccines in Healthy Infants and Toddlers
This study evaluates the immunogenicity and safety of the meningococcal conjugate vaccine GSK 134612 in healthy infants, when co-administered with other infant vaccines, on three different dose schedules.
Tutkimuksen yleiskatsaus
Tila
Valmis
Ehdot
Yksityiskohtainen kuvaus
This protocol has been updated following Protocol Amendment 1 date 26 July 2011 leading to the update of enrollment, a secondary outcome measure, intervention and exclusion criteria sections.
Opintotyyppi
Interventio
Ilmoittautuminen (Todellinen)
753
Vaihe
- Vaihe 3
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
1 kuukausi - 2 kuukautta (Lapsi)
Hyväksyy terveitä vapaaehtoisia
Joo
Sukupuolet, jotka voivat opiskella
Kaikki
Kuvaus
Inclusion Criteria:
- Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) [LAR(s)] can and will comply with the requirements of the protocol.
- A male or female, 6 to 12 weeks (42-90 days) of age at the time of the first vaccination.
- Written informed consent obtained from the parent(s)/LAR(s) of the subject.
- Healthy subjects as established by medical history and clinical examination before entering into the study.
- Born after a gestation period of at least 36 weeks.
Exclusion Criteria:
- Child in care.
- Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- Extended administration of immunosuppressants or other immune-modifying drugs since birth.
- Planned administration/administration of a vaccine not foreseen by the study protocol during the period 30 days before and after each study vaccine administration, with the exception of rotavirus vaccine and seasonal or pandemic influenza vaccine.
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
- Previous vaccination against diphtheria , tetanus, pertussis, polio (with the exception of a birth dose of OPV), Haemophilus influenzae type b, Streptococcus pneumonia.
- History of receipt of meningococcal vaccine.
- Subjects who received a birth dose Hepatitis B vaccines within the 30 days before the administration of the first study vaccine.
- History of or intercurrent diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b disease, pneumococcal and/or meningococcal disease.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- Family history of congenital or hereditary immunodeficiency.
- History of any reaction or hypersensitivity likely to be exacerbated by any component of th
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Ennaltaehkäisy
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Nimenrix 3+1 Group
Subjects, male and female, received 4 doses of Nimenrix™ vaccine (3 doses at 2, 4 and 6 months of age followed by a booster dose at 15-18 months of age) and 4 doses of Synflorix™ and Infanrix-IPV/Hiberix™ vaccines (at 2, 4, 6 and 15-18 months of age).
All vaccines were administered intramuscularly (IM) in the anterolateral region of the thigh.
|
Intramuscular injection
Intramuscular injection
Intramuscular injection
|
|
Kokeellinen: Nimenrix 1+1 Group
Subjects, male and female, received 2 doses of Nimenrix™ vaccine (1 dose at 6 months of age followed by a booster dose at 15-18 months of age) and 4 doses of Synflorix™ and Infanrix-IPV/Hiberix™ vaccines (at 2, 4, 6 and 15-18 months of age).
All vaccines were administered intramuscularly (IM) in the anterolateral region of the thigh.
|
Intramuscular injection
Intramuscular injection
Intramuscular injection
|
|
Kokeellinen: Nimenrix Control Group
Subjects, male and female, received 1 dose of Nimenrix™ at 15-18 months of age and 4 doses of Synflorix™ and Infanrix-IPV/Hiberix™ vaccines (at 2, 4, 6 and 15-18 months of age).
All vaccines were administered intramuscularly (IM) in the anterolateral region of the thigh.
|
Intramuscular injection
Intramuscular injection
Intramuscular injection
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Number of Subjects With Serum Bactericidal Assay Using Rabbit Complement (rSBA) Against Neisseria Meningitidis Serogroups Antibody Titers Greater Than or Equal to (≥) 1:8, One Month Post Dose 3 for the Nimenrix 3+1 Group
Aikaikkuna: At Month 5 (one month post-dose 3)
|
The cut-off value for the rSBA titers was ≥ 1:8.
Neisseria meningitidis serogroups A, C, W-135, Y (rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY) antibodies were assessed.
|
At Month 5 (one month post-dose 3)
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers Greater Than or Equal to (≥) 1:8 Prior to and One Month After the Booster Dose for the Nimenrix 3+1 Group
Aikaikkuna: At Month 13 (prior booster) and at Month 14 (one month after the booster dose)
|
The cut-off value for the rSBA titers was ≥ 1:8
|
At Month 13 (prior booster) and at Month 14 (one month after the booster dose)
|
|
Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers Greater Than or Equal to (≥) 1:128, One Month Post-dose 3, Prior to and One Month After the Booster Dose for the Nimenrix 3+1 Group
Aikaikkuna: At Months 5 (one month post-dose 3), 13 (prior booster-dose) and 14 (one month after the booster dose)
|
The cut-off value for the rSBA titers was ≥ 1:128
|
At Months 5 (one month post-dose 3), 13 (prior booster-dose) and 14 (one month after the booster dose)
|
|
rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers One Month Post Dose 3, Prior to and One Month After the Booster Dose for the Nimenrix 3+1 Group
Aikaikkuna: At Months 5 (one month post-dose 3), 13 (prior booster-dose) and 14 (one month after the booster dose)
|
Antibody titers are presented as geometric mean titers (GMTs).
|
At Months 5 (one month post-dose 3), 13 (prior booster-dose) and 14 (one month after the booster dose)
|
|
Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers Greater Than or Equal to (≥) the Cut-off Values for the Nimenrix 1+1 and Nimenrix Control Groups
Aikaikkuna: At Months 5 (one month post-primary dose for Nimenrix 1+1 Group), 13 (prior booster dose for Nimenrix 1+1 and prior primary dose for Nimenrix Control Group) and 14 (post booster dose for Nimenrix 1+1 and post-primary dose for Nimenrix Control Group)
|
The cut-off values for the rSBA antibody titers were ≥ 1:8 and ≥ 1:128
|
At Months 5 (one month post-primary dose for Nimenrix 1+1 Group), 13 (prior booster dose for Nimenrix 1+1 and prior primary dose for Nimenrix Control Group) and 14 (post booster dose for Nimenrix 1+1 and post-primary dose for Nimenrix Control Group)
|
|
rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers for Nimenrix 1+1 and Nimenrix Control Groups
Aikaikkuna: At Months 5 (one month post-primary dose for Nimenrix 1+1 Group), 13 (prior booster dose for Nimenrix 1+1 and prior primary dose for Nimenrix Control Group) and 14 (post booster dose Nimenrix 1+1 and post-primary dose for Nimenrix Control Group)
|
Antibody titers are presented as geometric mean titers (GMTs).
|
At Months 5 (one month post-primary dose for Nimenrix 1+1 Group), 13 (prior booster dose for Nimenrix 1+1 and prior primary dose for Nimenrix Control Group) and 14 (post booster dose Nimenrix 1+1 and post-primary dose for Nimenrix Control Group)
|
|
Number of Subjects With Booster Responses for rSBA-MenA, C rSBA-MenC, Y rSBA-MenY and W-135 rSBA-MenW-135 in Nimenrix 3+1 and Nimenrix 1+1 Groups and With Vaccine Response in Nimenrix Control Group
Aikaikkuna: At Month 14 (one month post-booster dose for Nimenrix 3+1 and Nimenrix 1+1 and post-primary dose for Nimenrix Control Group)
|
Vaccine/Booster response was defined as: for seronegative subjects (rSBA titers < 1:8 pre-vaccination at Month 13), antibody titer ≥ 1:32 at post vaccination; for seropositive subjects (rSBA titers >= 1:8 pre-vaccination at Month 13), antibody titer at post vaccination ≥ 4-fold the pre vaccination antibody titer.
|
At Month 14 (one month post-booster dose for Nimenrix 3+1 and Nimenrix 1+1 and post-primary dose for Nimenrix Control Group)
|
|
Number of Subjects With Serum Bactericidal Assay Using Human Complement Against Neisseria Meningitidis Serogroups A, C, W-135, Y Antibody Titers Greater Than or Equal to (≥) the Cut-off Values (One Month Post-primary for Nimenrix 3+1 and 1+1 Groups)
Aikaikkuna: At Month 5 (one month post-primary for Nimenrix 3+1 and Nimenrix 1+1 Groups)
|
The cut-off value for the hSBA titers was ≥ 1:4 and ≥ 1:8.
|
At Month 5 (one month post-primary for Nimenrix 3+1 and Nimenrix 1+1 Groups)
|
|
hSBA-MenA, hSBA-MenC, hSBA-MenW-135, and hSBA-Men-Y Antibody Titers (One Month Post-primary for Nimenrix 3+1 and Nimenrix 1+1 Groups)) -Randomized Subset of 50% of Subjects of All Three Groups
Aikaikkuna: At Month 5 (one month post-primary for Nimenrix 3+1 and Nimenrix 1+1 Groups)
|
Antibody titers are presented as geometric mean titers (GMTs).
|
At Month 5 (one month post-primary for Nimenrix 3+1 and Nimenrix 1+1 Groups)
|
|
Number of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-Men-Y Titers (≥) the Cut-off Value (Pre- and Post-booster for Nimenrix 3+1 and 1+1 Groups and Pre- and Post-vaccination for Nimenrix Control)
Aikaikkuna: At Month 13 (pre-booster for Nimenrix 3+1 and Nimenrix 1+1 Groups and pre-vaccination for Nimenrix Control), and at Month 14 (post-booster for Nimenrix 3+1 and Nimenrix 1+1 Groups and post-vaccination for Nimenrix Control)
|
The cut-off value for the hSBA titers was ≥ 1:4 and ≥ 1:8.
|
At Month 13 (pre-booster for Nimenrix 3+1 and Nimenrix 1+1 Groups and pre-vaccination for Nimenrix Control), and at Month 14 (post-booster for Nimenrix 3+1 and Nimenrix 1+1 Groups and post-vaccination for Nimenrix Control)
|
|
hSBA-MenA, hSBA-MenC, hSBA-MenW-135, and hSBA-Men-Y Antibody Titers (Pre-booster for Nimenrix 3+1 and 1+1 Groups and Pre-vaccination for Nimenrix Control, and Post-booster for Nimenrix 3+1 and 1+1 Groups and Post-vaccination for Nimenrix Control)
Aikaikkuna: At Month 13 (pre-booster for Nimenrix 3+1 and Nimenrix 1+1 Groups and pre-vaccination for Nimenrix Control), and at Month 14 (post-booster for Nimenrix 3+1 and Nimenrix 1+1 Groups and post-vaccination for Nimenrix Control)
|
Antibody titers are presented as geometric mean titers (GMTs).
|
At Month 13 (pre-booster for Nimenrix 3+1 and Nimenrix 1+1 Groups and pre-vaccination for Nimenrix Control), and at Month 14 (post-booster for Nimenrix 3+1 and Nimenrix 1+1 Groups and post-vaccination for Nimenrix Control)
|
|
Number of Subjects With Booster Responses for hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY in Nimenrix 3+1 and Nimenrix 1+1 Groups and With Vaccine Response in Nimenrix Control Group
Aikaikkuna: At Month 14 (one month after the booster dose in Nimenrix 3+1 and Nimenrix 1+1 and post-vaccination in Nimenrix Control Group)
|
Vaccine/Booster response was defined as: for seronegative subjects (rSBA titers < 1:4 pre-vaccination at Month 13), antibody titer ≥ 1:32 at post vaccination; for seropositive subjects (rSBA titers >= 1:4 pre-vaccination at Month 13), antibody titer at post vaccination ≥ 4-fold the pre vaccination.
|
At Month 14 (one month after the booster dose in Nimenrix 3+1 and Nimenrix 1+1 and post-vaccination in Nimenrix Control Group)
|
|
Number of Subjects With Anti-pneumococcal Antibody Concentrations Greater Than or Equal to (≥) 0.15 Micrograms Per Milliliter (µg/mL).
Aikaikkuna: At Months 5 (one month post-dose 3), Month 13 (prior booster dose) and Month 14 (one month after the booster dose)
|
The anti-pneumococcal serotypes assessed were 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.
|
At Months 5 (one month post-dose 3), Month 13 (prior booster dose) and Month 14 (one month after the booster dose)
|
|
Number of Subjects With Anti-pneumococcal Antibody Concentrations Greater Than or Equal to (≥) 0.35 Micrograms Per Milliliter (µg/mL)
Aikaikkuna: At Months 5 (one month post-dose 3), Month 13 (prior booster dose) and Month 14 (one month after the booster dose)
|
The anti-pneumococcal serotypes assessed were 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.
|
At Months 5 (one month post-dose 3), Month 13 (prior booster dose) and Month 14 (one month after the booster dose)
|
|
Anti-pneumococcal Antibody Concentrations
Aikaikkuna: At Months 5 (one month post-dose 3), Month 13 (prior booster-dose) and Month 14 (one month after the booster dose)
|
Antibody concentrations were expressed as Geometric Mean Concentrations (GMCs) and measured in micrograms/milliliter (µg/mL)
|
At Months 5 (one month post-dose 3), Month 13 (prior booster-dose) and Month 14 (one month after the booster dose)
|
|
Number of Subjects With Anti-diphtheria (Anti-D) Antibodies
Aikaikkuna: At Month 5 (one month post-dose 3)
|
Cut-off values assessed were greater than or equal to (≥) 0.1 international units per milliliter (IU/mL).
|
At Month 5 (one month post-dose 3)
|
|
Concentration of Antibodies Against Diphtheria Antigens (Anti-D)
Aikaikkuna: At Month 5 (one month post-dose 3)
|
Concentrations are presented as geometric mean concentrations (GMCs) expressed in international units per milliliter (IU/mL).
|
At Month 5 (one month post-dose 3)
|
|
Concentration of Antibodies Against Diphtheria Antigens (Anti-D)
Aikaikkuna: At Month 5 (one month post-dose 3)
|
Concentrations are presented as geometric mean concentrations (GMCs) expressed in international units per milliliter (IU/mL).
The analysis was performed in a randomized subset of 25% of subjects of all three groups.
Note: As the percentage of subjects with serological results excluded from the ATP cohorts was higher than 5%, a second analysis based on the total vaccinated cohorts (TVCs) (Primary and Booster) was performed to complement the ATP analysis.
|
At Month 5 (one month post-dose 3)
|
|
Concentration of Antibodies Against Pertussis Toxoid (Anti-PT), Filamentous Haemagglutinin (Anti-FHA), Pertactin (Anti-PRN) Antigens
Aikaikkuna: At Month 5 (one month post-dose 3)
|
Concentrations are presented as geometric mean concentrations (GMCs) expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/ml).
|
At Month 5 (one month post-dose 3)
|
|
Number of Subjects With Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA), Anti-pertactin (Anti-PRN) Immunoglobulin G (IgG) Antibodies
Aikaikkuna: At Month 5 (one month post-dose 3)
|
Cut-off values assessed were greater than or equal to ≥ 5 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/ml).
|
At Month 5 (one month post-dose 3)
|
|
Antibody Titers for Anti-polio Type 1, 2 and 3 Antibodies
Aikaikkuna: At Month 5 (one month post-dose 3)
|
Antibody titers are presented as geometric mean titers (GMTs).
|
At Month 5 (one month post-dose 3)
|
|
Antibody Titers for Anti-polio Type 1, 2 and 3 Antibodies
Aikaikkuna: At Month 5 (one month post-dose 3)
|
Antibody titers are presented as geometric mean titers (GMTs).
The analysis was performed in a randomized subset of 25% of subjects of all three groups.
Note: As the percentage of subjects with serological results excluded from the ATP cohorts was higher than 5%, a second analysis based on the total vaccinated cohorts (TVCs) (Primary and Booster) was performed to complement the ATP analysis.
|
At Month 5 (one month post-dose 3)
|
|
Number of Subjects With Anti-tetanus (Anti-T) Antibodies
Aikaikkuna: At Months 5 (one month post-dose 3), Month 13 (prior booster-dose) and Month 14 (one month after the booster dose)
|
Cut-off values assessed were greater than or equal to (≥) 0.1 international units per milliliter (IU/mL).
|
At Months 5 (one month post-dose 3), Month 13 (prior booster-dose) and Month 14 (one month after the booster dose)
|
|
Concentration of Antibodies Against Tetanus Antigens (Anti-T)
Aikaikkuna: At Months 5 (one month post-dose 3), Month 13 (prior booster-dose) and Month 14 (one month after the booster dose)
|
Concentrations are presented as geometric mean concentrations (GMCs) expressed in international units per milliliter (IU/mL).
|
At Months 5 (one month post-dose 3), Month 13 (prior booster-dose) and Month 14 (one month after the booster dose)
|
|
Number of Subjects With Anti-tetanus (Anti-T) Antibodies
Aikaikkuna: At Months 5 (one month post-dose 3), 13 (prior booster-dose) and 14 (one month after the booster dose)
|
Cut-off values assessed were greater than or equal to (≥) 0.1 international units per milliliter (IU/mL).
The analysis was performed in a randomized subset of 25% of subjects of all three groups.
Note: As the percentage of subjects with serological results excluded from the ATP cohorts was higher than 5%, a second analysis based on the total vaccinated cohorts (TVCs) (Primary and Booster) was performed to complement the ATP analysis.
|
At Months 5 (one month post-dose 3), 13 (prior booster-dose) and 14 (one month after the booster dose)
|
|
Anti-PRP Antibody Concentrations (Geometric Mean Concentrations) in a Randomized Subset of 25% of the Subjects
Aikaikkuna: At Month 5 (one month post-dose 3)
|
The endpoints evaluating immunogenicity of the Hib component (anti-polyribosyl ribitol phosphate [anti-PRP] antibody concentrations) has been cancelled owing to the extended delay in the re-development and re-validation of the PRP assay.
|
At Month 5 (one month post-dose 3)
|
|
Number of Subjects With Solicited Local Symptoms (Primary Phase)
Aikaikkuna: Within 8 days (Day 0-7) post primary vaccination
|
Assessed solicited local symptoms were pain, redness and swelling.
Any = occurrence of the symptom regardless of intensity grade.
Grade 3 pain = pain that prevented normal activity.
Grade 3 redness/swelling = redness/swelling spreading beyond 30 millimeters (mm) of injection site.
|
Within 8 days (Day 0-7) post primary vaccination
|
|
Number of Subjects With Solicited Local Symptoms (Booster Phase)
Aikaikkuna: Within 8 days (Day 0-7) post booster vaccination
|
Assessed solicited local symptoms were pain, redness and swelling.
Any = occurrence of the symptom regardless of intensity grade.
Grade 3 pain = pain that prevented normal activity.
Grade 3 redness/swelling = redness/swelling spreading beyond 30 millimeters (mm) of injection site.
|
Within 8 days (Day 0-7) post booster vaccination
|
|
Number of Subjects With Solicited General Symptoms (Primary Phase)
Aikaikkuna: Within 8 days (Day 0-7) post primary vaccination
|
Assessed solicited general symptoms were temperature [defined as rectally temperature equal to or above 38 degrees Celsius (°C)], drowsiness, irritability and loss of appetite.
Any = occurrence of the symptom regardless of intensity grade.
Grade 3 symptom = symptom that prevented normal activity.
Grade 3 temperature = temperature > 40.0 °C.
Related = symptom assessed by the investigator as related to the vaccination.
|
Within 8 days (Day 0-7) post primary vaccination
|
|
Number of Subjects With Solicited General Symptoms (Booster Phase)
Aikaikkuna: Within 8 days (Day 0-7) post booster vaccination
|
Assessed solicited general symptoms were temperature [defined as rectally temperature equal to or above 38 degrees Celsius (°C)], drowsiness, irritability and loss of appetite.
Any = occurrence of the symptom regardless of intensity grade.
Grade 3 symptom = symptom that prevented normal activity.
Grade 3 temperature = temperature > 40.0 °C.
Related = symptom assessed by the investigator as related to the vaccination.
|
Within 8 days (Day 0-7) post booster vaccination
|
|
Number of Subjects With Unsolicited Adverse Events (AEs) (Primary Phase)
Aikaikkuna: Within 31 days (Day 0-30) post each primary vaccine dose
|
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
|
Within 31 days (Day 0-30) post each primary vaccine dose
|
|
Number of Subjects With Unsolicited Adverse Events (AEs) (Booster Phase)
Aikaikkuna: Within 31 days (Day 0-30) post booster vaccination
|
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
|
Within 31 days (Day 0-30) post booster vaccination
|
|
Number of Subjects With New Onset of Chronic Illnesses (NOCIs)
Aikaikkuna: From Day 0 to Month 19
|
NOCIs include autoimmune disorders, asthma, type I diabetes, allergies.
|
From Day 0 to Month 19
|
|
Number of Subjects With Serious Adverse Events (SAEs)
Aikaikkuna: From Day 0 to Month 19
|
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
|
From Day 0 to Month 19
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Julkaisuja ja hyödyllisiä linkkejä
Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Perjantai 27. tammikuuta 2012
Ensisijainen valmistuminen (Todellinen)
Maanantai 4. elokuuta 2014
Opintojen valmistuminen (Todellinen)
Maanantai 19. lokakuuta 2015
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Torstai 14. huhtikuuta 2011
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Torstai 21. huhtikuuta 2011
Ensimmäinen Lähetetty (Arvio)
Maanantai 25. huhtikuuta 2011
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Tiistai 6. elokuuta 2019
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Tiistai 11. kesäkuuta 2019
Viimeksi vahvistettu
Lauantai 1. kesäkuuta 2019
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 114858
- 2013-002537-37 (EudraCT-numero)
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Ei
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Ei
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .